Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CIZWI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AMT-676
|
|||||
| Synonyms |
AMT-676a; AMT-676a ADC; AMT-676
Click to Show/Hide
|
|||||
| Organization |
Multitude Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CDH17 antibody
|
Antibody Info | ||||
| Antigen Name |
Cadherin-17 (CDH17)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
T1000
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
sesutecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have unresectable advanced solid tumors (e.g., colorectal, gastric, or pancreatic cancers), ECOG 0-1, and adequate organ function. Key exclusions include prior ADC/targeted therapy, CNS metastasis, active infections, severe cardiac/respiratory conditions, recent major surgery/radiation, pregnancy, or concurrent investigational treatment.
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06400485 | Clinical Status | EARLY_PHASE1 | ||
| Clinical Description | First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study focuses on determining the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) and safety profiles, with assessments within 30 days post-dosing. Adverse events will also be evaluated using CTCAE v5.0 for severity and incidence.
|
||||
| Other Endpoint |
Pharmacokinetic parameters such as Cmax, Tmax, AUC, and t1/2 of AMT-676 will be measured within 30 days post-dosing. Immunogenicity will be assessed via anti-drug antibody (ADA) levels, while efficacy endpoints include ORR (CR/PR), DCR (CR/PR/SD), and PFS per RECIST v1.1.
|
||||